Change in Ingredient Scopolamine Butylbromide to HYOSCINE BUTYLBROMIDE in CCDD

In January 2019, the CCDD team chose to use the term scopolamine butylbromide over hyoscine butylbromide in the CCDD, despite the fact hyoscine butylbromide is used in Health Canada’s Drug Product Database. The two terms are synonyms, and since scopolamine HYDRObromide is also in DPD, this would allow the use of only one term, scopolamine, for both concepts, i.e., scopolamine HYDRObromide and scopolamine BUTYLbromide. However, although CCDD is designed as an interchange terminology, some users may choose to use CCDD terminology in their clinician-facing interface. This may present confusion since this ingredient is generally known in clinical practice as hyoscine butylbromide.

We therefore, have made the decision to revert to using hyoscine butylbromide in our terminology with the following rationale:
• Hyoscine butylbromide and scopolamine butylbromide are synonyms.
• Scopolamine hydrobromide and scopolamine (hyoscine) butylbromide are structurally different base compounds. Scopolamine butylbromide is more accurately described as butylscopolamine bromide.
• The current TMs (scopolamine hydrobromide and scopolamine butylbromide) are visually similar, which could result in erroneous selection in a picklist.
• Each ingredient has different indications.
• Changing the name to hyoscine butylbromide will not introduce new NTPs with duplicate meaning to existing concepts.

The change to hyoscine butylbromide is planned for the August 2022 CCDD release. Scopolamine hydrobromide will remain unchanged.

For additional background information, please see the previous presentation 20190123 - Hyoscine or Scopolamine Discussion - InfoCentral (infoway-inforoute.ca) .

To provide feedback before July 25, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..